The Healthcare Cost Burden in Adults with High Risk for Cardiovascular Disease

PharmacoEconomics - Open - Tập 5 - Trang 425-435 - 2021
Dat T. Tran1,2, Dan Palfrey1, Robert Welsh3
1Institute of Health Economics, Edmonton, Canada
2Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Canada
3Faculty of Medicine, University of Alberta, Edmonton, Canada

Tóm tắt

We calculated the short- and long-term care resource use and costs in adults with high-risk conditions for cardiovascular disease (HRCVD) as defined by the Canadian Cardiovascular Society dyslipidemia guidelines. We linked Alberta health databases to identify patients aged ≥ 18 years with HRCVD between fiscal year (FY) 2012 and FY2016. The first HRCVD event was the index event. Patients were categorized into (1) primary prevention patients and (2) secondary prevention patients at the index event and were followed until death, they moved out of the province, or they were censored at March 2018. We calculated the resource use and costs for each of the 5 years after the index event. The study included 459,739 HRCVD patients (13,947 [3%] were secondary prevention patients). The secondary prevention patients were older (median age 61 years vs. 55 years; p < 0.001), and there were fewer females in this group (30.4% vs. 51.3%; p < 0.001). The total healthcare costs in the first year decreased over time (FY2012: 1.16 billion Canadian dollars (CA$); FY2016: CA$1.05 billion; p < 0.001). An HRCVD patient incurred CA$12,068, CA$5626, and CA$4655 during the first, second, and fifth year, respectively (p for trend < 0.001). During the first year, healthcare costs per secondary prevention patient (CA$36,641) were triple that for a primary prevention patient (CA$11,299; p < 0.001), primarily due to higher hospitalization costs in secondary prevention patients (CA$26,896 vs. CA$6051; p < 0.001). The healthcare costs for HRCVD patients were substantial but decreased over time. The costs were highest in the year following the index event and decreased thereafter. Secondary prevention patients incurred higher costs than the primary prevention patients.

Tài liệu tham khảo

Heidenreich PA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123(8):933–44.

Leal J, et al. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J. 2006;27:1610–9.

Public Health Agency of Canada. Tracking heart disease and stroke in Canada, 2009, viii. Ottawa: Public Health Agency of Canada; 2009.

Collaboration CTT. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81.

Grundy SM, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082–143.

Anderson TJ, et al. 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Can J Cardiol. 2016;32(11):1263–82.

Brunham LR, et al. Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018. Can J Cardiol. 2018;34(12):1553–63.

Tran DT, et al. Outcome and Cost of Optimal Control of Dyslipidemia in Adults with High Risk for Cardiovascular Disease. Can J Cardiol. 2021;37(1):66–76.

Alberta Health. Overview of Administrative Health Datasets. 2017 April 28, 2017. https://open.alberta.ca/dataset/657ed26d-eb2c-4432-b9cb-0ca2158f165d/resource/38f47433-b33d-4d1e-b959-df312e9d9855/download/Research-Health-Datasets.pdf. Accessed 3 Octo 2020.

Canadian Institute for Health Information. Cost of a Standard Hospital Stay 2019. http://yourhealthsystem.cihi.ca/inbrief/?lang=en&_ga=2.233170907.456686591.1556912958-199991464.1544733065#!/indicators/015/cost-of-a-standard-hospital-stay/;mapC1;mapLevel2;trend(C1,C20018). Accessed 3 May 2019.

Canadian Institute for Health Information. Cost of a standard hospital stay: appendices to indicator library—methodology notes. Canadian Ottawa: Institute for Health Information; 2017.

Alberta Health. Interactive Drug Benefit List. 2018. https://www.ab.bluecross.ca/dbl/publications.html. Accessed 10 May 2018

Statistics Canada. Table 326-0020: Consumer Price Index (CPI). June 6, 2018. http://www5.statcan.gc.ca/cansim/a26?lang=eng&retrLang=eng&id=3260020&&pattern=&stByVal=1&p1=1&p2=37&tabMode=dataTable&csid=. Accessed 3 May 2019.

Quan H, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–9.

Tran DT, et al. Resource use and burden of hospitalization, outpatient, physician, and drug costs in short- and long-term care after acute myocardial infarction. Can J Cardiol. 2018;34(10):1298–306.

Tran DT, et al. The healthcare cost burden of acute myocardial infarction in Alberta, Canada. Pharmacoecon Open. 2017;2(4):433–42.

Tran DT, et al. The current and future financial burden of hospital admissions for heart failure in Canada: a cost analysis. CMAJ Open. 2016;4(3):E365–70.

Heidenreich PA, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6(3):606–19.

Statistics Canada. Cholesterol levels of adults, 2012 to 2013. https://www150.statcan.gc.ca/n1/pub/82-625-x/2014001/article/14122-eng.htm. Accessed 9 July 2019.

Statistics Canada. Table: 17-10-0057-01 (formerly CANSIM 052-0005) - Projected population, by projection scenario, age and sex, as of July 1 (x 1,000). CANSIM (database). http://www5.statcan.gc.ca/cansim/pick-choisir?lang=eng&p2=33&id=0520005. Accessed 7 Feb 2018.

Reddy K, Khaliq A, Henning RJ. Recent advances in the diagnosis and treatment of acute myocardial infarction. World J Cardiol. 2015;7(5):243–76.

Chen G, et al. Treatment and low-density lipoprotein cholesterol management in patients diagnosed with clinical atherosclerotic cardiovascular disease in Alberta. Can J Cardiol. 2019;35(7):884–91.

Bradley CK, et al. Patient-reported reasons for declining or discontinuing statin therapy: insights from the PALM Registry. J Am Heart Assoc. 2019;8(7):e011765.

Balu S, et al. Impact of fixed-dose and multi-pill combination dyslipidemia therapies on medication adherence and the economic burden of sub-optimal adherence. Curr Med Res Opin. 2009;25(11):2765–75.

Gaziano TA, et al. Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States. Am Heart J. 2019;214:77–87.

Gibson TB, et al. Impact of statin copayments on adherence and medical care utilization and expenditures. Am J Manag Care. 2006;12:11–9.

Wu R, et al. Feasibility of using a smartwatch to intensively monitor patients with chronic obstructive pulmonary disease: prospective cohort study. JMIR Mhealth Uhealth. 2018;6(6):e10046.

Tran DT, et al. Current and future direct healthcare cost burden of chronic obstructive pulmonary disease in Alberta, Canada. Can J Respir Crit Care Sleep Med. 2019;4(1):39–47.

Yusuf S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–52.

Kahn R, et al. The impact of prevention on reducing the burden of cardiovascular disease. Circulation. 2008;118(5):576–85.

Yang W, et al. The effectiveness and cost-effectiveness of plant sterol or stanol-enriched functional foods as a primary prevention strategy for people with cardiovascular disease risk in England: a modeling study. Eur J Health Econ. 2018;19(7):909–22.

Stabile M, et al. Health care cost containment strategies used in four other high-income countries hold lessons for the United States. Health Aff (Millwood). 2013;32(4):643–52.

Thông tin
Thông tin xuất bản

PharmacoEconomics - Open

Tập 5

425-435

Thông tin tác giả